FTO inhibition drives MYC inhibition. The original CoH paper shows that Zan inhibits FTO which in turn influences MYC expression.
Prior preclinical models have shown Zantrene is functioning as a cardioprotective agent independently of FTO.
Unsure if that's the pathway, but I'd say not. A good way I like to think about it is if you turn a tree upside down - the trunk is cellular function as a whole, a main branch is FTO, and an offshoot from that main branch is MYC. You can't impact MYC without inhibiting FTO.
Ann: Bisantrene shows potent anticancer activity in AML models, page-80
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.75 |
Change
0.180(11.5%) |
Mkt cap ! $296.8M | |||
| Open | High | Low | Value | Volume |
| $1.58 | $1.80 | $1.58 | $772.4K | 450.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2354 | $1.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.76 | 525 | 1 |
View Market Depth
| Last trade - 16.10pm 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.75 |
Change
0.180 ( 11.2 %) |
||||
| Open | High | Low | Volume | ||
| $1.60 | $1.80 | $1.58 | 22024 | ||
| Last updated 15.59pm 06/06/2024 ? | |||||
| RAC (ASX) Chart |